Skip to main content

Table 2 Outcomes Among Acute Minor Ischemic Stroke Patients With and Without AF

From: Short- and long-term outcomes of patients with minor stroke and nonvalvular atrial fibrillation

Outcomes

N(%)

Unadjusted

Adjusted

NVAF

Non-AF

HR (95% CI)

P value

HR (95% CI)

P value

In-hospital

 All-cause mortality

0 (0)

3 (0.07)

-

 

-

 

 Cardiovascular mortality

0 (0)

3 (0.07)

-

  

-

 Recurrent ischemic stroke

8 (3.6)

226 (4.99)

0.73 (0.36,1.48)

0.38

0.45 (0.19,1.05)

0.07

 Hemorrhagic stroke

1 (0.45)

6 (0.13)

2.46 (0.22,27.27)

0.46

-

 

3 months

 All-cause mortality

2 (0.9)

29 (0.64)

1.41 (0.34,5.90)

0.64

1.11 (0.24,5.10)

0.90

 Cardiovascular mortality

2 (0.9)

21 (0.46)

1.94 (0.46,8.29)

0.37

1.82 (0.37,8.96)

0.46

 Recurrent ischemic stroke

10 (4.5)

293 (6.47)

0.69 (0.37,1.30)

0.25

0.33 (0.16,0.68)

0.003

 Hemorrhagic stroke

3 (1.35)

18 (0.4)

3.41 (1.00,11.57)

0.05

3.62 (0.69,19.01)

0.13

6 months

 All-cause mortality

4 (1.8)

44 (0.97)

1.85 (0.67,5.16)

0.24

1.12 (0.34,3.65)

0.86

 Cardiovascular mortality

3 (1.35)

26 (0.57)

2.36 (0.71,7.78)

0.16

1.96 (0.49,7.82)

0.34

 Recurrent ischemic stroke

15 (6.76)

339 (7.48)

0.89 (0.53,1.50)

0.67

0.49 (0.27,0.89)

0.02

 Hemorrhagic stroke

3 (1.35)

24 (0.53)

2.56 (0.77,8.50)

0.12

2.82 (0.61,13.13)

0.19

1 year

 All-cause mortality

12 (5.41)

72 (1.59)

3.45 (1.87,6.35)

< 0.001

1.96 (0.92,4.15)

0.08

 Cardiovascular mortality

7 (3.15)

35 (0.77)

4.13 (1.84,9.31)

< 0.001

4.66 (1.79,12.15)

0.001

 Recurrent ischemic stroke

19 (8.56)

408 (9)

0.94 (0.60,1.50)

0.81

0.55 (0.32,0.94)

0.03

 Hemorrhagic stroke

5 (2.25)

34 (0.75)

3.04 (1.19,7.77)

0.02

2.83 (0.83,9.61)

0.10

  1. AF, indicates atrial fibrillation; NVAF, nonvalvular atrial fibrillation. Adjustment covariates includes age, current smoking, diabetes mellitus, prior CAD, heart failure, BMI, onset to door time, blood creatinine, admission SBP, admission DBP, medication history of antiplatelet and anticoagulant, treatment of antiplatelet, anticoagulant, and glucose-lowering agents